<DOC>
	<DOC>NCT00234520</DOC>
	<brief_summary>The aim of the study is to compare the risk of acromegaly patients developing valvular regurgitation when receiving lanreotide or octreotide</brief_summary>
	<brief_title>A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Patient has a diagnosis of Acromegaly Patient is being treated with lanreotide or octreotide in any dose form at the selection visit or is a de novo patient who is due to commence treatment within 2 weeks of baseline Patient started treatment with either lanreotide or octreotide when both products were available on the market in their country Patient must not change treatment form lanreotide to octreotide or vice versa for the duration of the study Patients with known significant valve abnormalities prior to treatment with either lanreotide or octreotide Patients who have received treatment with a somatostatin analogue other than lanreotide or octreotide for more than 3 months Patients who have received treatment with a GH antagonist for more than 3 months Patients who have had heart valve replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>